Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
  • FREE for Members
  • Pharmacology CE
  • Contact hours
$10.00
1.0 contact hour of which 1.25 contain pharmacology content. This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $10. Clostridioides difficile infection (CDI) is a major public health concern for pediatric and adult patients. The management of pediatric CDI poses a challenge to healthcare providers due to lack of strong randomized controlled trials to guide pharmacological management. Additionally, recent updates to CDI guidelines recommend oral vancomycin over metronidazole for the management of CDI in adults, leaving questions regarding how to best manage pediatric patients. This continuing education pharmacotherapy review describes available evidence for the safety and efficacy of medications used in the treatment and management of pediatric CDI and aims to clarify discrepancies between pediatric and adult recommendations.
  • Primary Care
  • Acute Care
  • FREE for Members
  • Infectious Disease
  • Immunization
  • Pharmacology CE
  • Contact hours
$12.50
1.25 NAPNAP Pharmacology Contact Hour. This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $12.50. While sharing the latest CDC immunization information, Dr. Koslap-Petraco will share real life experiences and case studies to engage and challenge you to educate and vaccinate your patient families, especially those who question the need for vaccines.
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • Contact hours
$10.00
1.0 NAPNAP contact hour, 1.0 pharmacology contact hour. This continuing education activity is offered free to NAPNAP Members. For non-members, this continuing education activity rate is $10. Before 2018, there were no U.S. Food and Drug Administration approved medications for managing seizures in Dravet syndrome (DS). Common agents used in the antiepileptic drug regimens of patients with DS included clobazam, valproic acid, topiramate, and levetiracetam, among others; however, these agents alone rarely provide adequate seizure control. Management of seizures in DS changed in recent years with the approval of cannabidiol and stiripentol in 2018 and fenfluramine in 2020. This continuing education article summarizes available efficacy and safety data involving cannabidiol, stiripentol, and fenfluramine and provides a practical review of dosing strategies, pharmacokinetics, and monitoring interventions relevant to their use. J Pediatr Health Care. (2022) 36, 479−488